Veru/VERU

$1.29

-5.84%
-
1D1W1MYTD1YMAX

About Veru

Veru Inc. is a biopharmaceutical company. The Company is focused on developing medicines for the for the treatment of hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and other viral-related ARDS and for the management of breast and prostate cancers. The Company offers two FDA approved products within its sexual health program, including ENTADFI (tadalafil 5mg and finasteride 5mg capsule), for the treatment of benign prostatic hyperplasia and FC2 Female Condom (internal condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.

Ticker

VERU

Sector

Consumer Non-Cyclicals

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Mitchell Steiner

Employees

189

Headquarters

Miami, United States

Veru Metrics

BasicAdvanced
$215M
Market cap
-
P/E ratio
-$0.35
EPS
-0.30
Beta
-
Dividend rate
$215M
-0.30023
$1.92
$0.36
2.5M
4.718
4.216
19.41
21.513
-50.43%
-115.69%
-76.84%
15.964
4.76
5.614
-36.67%
79.49%
-27.4%

What the Analysts think about Veru

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 5 analysts.
166.67% upside
High $5.00
Low $1.20
$1.29
Current price
$3.44
Average price target

Veru Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-243.9% profit margin
QuarterlyAnnual
Q2 24
QoQ growth
Revenue
$4.1M
95.24%
Net income
-$10M
21.95%
Profit margin
-243.9%
-37.54%

Veru Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 31.25%
QuarterlyAnnual
Q3 23
Q4 23
Q1 24
Q2 24
Q3 24
Actual
$0.07
-$0.12
-$0.08
-$0.07
-
Expected
-$0.21
-$0.24
-$0.10
-$0.05
-$0.06
Surprise
-134.15%
-48.94%
-22.58%
31.25%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Veru stock?

Veru (VERU) has a market cap of $201M as of May 19, 2024.

What is the P/E ratio for Veru stock?

The price to earnings (P/E) ratio for Veru (VERU) stock is 0 as of May 19, 2024.

Does Veru stock pay dividends?

No, Veru (VERU) stock does not pay dividends to its shareholders as of May 19, 2024.

When is the next Veru dividend payment date?

Veru (VERU) stock does not pay dividends to its shareholders.

What is the beta indicator for Veru?

Veru (VERU) has a beta rating of -0.32. This means that it has an inverse relation to market volatility.

What is the Veru stock price target?

The target price for Veru (VERU) stock is $3.44, which is 160.61% above the current price of $1.32. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Veru stock

Buy or sell Veru stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing